Clinical Data Lilly’s Verve gambit pays off as base editor cuts cholesterol in early study BioSpaceA single 1-mg/kg dose of Eli Lilly's base editor can lower LDL cholesterol levels by 62% in patients with a heritable form of hypercholesterolemia.CardiovascularRead full story pharminent May 26, 2026 (Last updated: May 26, 2026) BioSpace A single 1-mg/kg dose of Eli Lilly’s base editor can lower LDL cholesterol levels by 62% in patients with a heritable form of hypercholesterolemia. Cardiovascular Read full story Post navigation Previous: Pierre Fabre’s Braftovi gains CHMP positive opinion for mCRCNext: Arthrosi drug trial in gout delivers for new owner Sobi Related Stories Clinical Data Novo Nordisk starts trialing lower maintenance doses of oral Wegovy pharminent August 21, 2026 Clinical Data Cancer vaccine win restores Wall Street’s faith in Moderna pharminent August 20, 2026 Clinical Data New Taiho, Cullian data heats up lung cancer drug battle pharminent August 13, 2026
